<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780104</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 02407</org_study_id>
    <nct_id>NCT00780104</nct_id>
  </id_info>
  <brief_title>Sirolimus in Combination With MEC in High Risk Myeloid Leukemias</brief_title>
  <acronym>UPCC 02407</acronym>
  <official_title>A Prospective Single Institution Pilot Study Evaluating the Pharmacokinetics of Sirolimus in Combination With MEC (Mitoxantrone + Etoposide + Cytarabine) in Patients With High Risk Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the side effects of sirolimus (rapamycin) given in
      combination with chemotherapy (Mitoxantrone + Etoposide + Cytarabine (MEC)) on high risk
      myeloid leukemias.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of biologic effects of rapamycin on mTOR targets such as p70 protein phosphorylation in leukemic cells</measure>
    <time_frame>Study conclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the sirolimus + MEC regimen</measure>
    <time_frame>Study conclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Myeloid Leukemias</condition>
  <condition>AML</condition>
  <condition>Leukemia</condition>
  <condition>CML</condition>
  <arm_group>
    <arm_group_label>Rapamycin + MEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin, Mitoxantrone, Etoposide, Cytarabine</intervention_name>
    <description>Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.</description>
    <arm_group_label>Rapamycin + MEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin + MEC</intervention_name>
    <description>Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.</description>
    <arm_group_label>Rapamycin + MEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have histologic evidence of advanced myeloid leukemias defined as one of the
             following: primary refractory non-M3 AML; relapsed non-M3 AML; secondary AML;
             intermediate or poor prognosis de novo AML in patients who are &gt;= 60 years old

          -  &gt;= 18 years of age

          -  ECOG performance status of 0, 1

          -  Able to consume oral medication

          -  Initial laboratory values: creatinine &lt;= 2.0 mg/dL; total or direct bilirubin &lt;=
             1.5/dL; SGPT(ALT) &lt;= 3xULN; negative pregnancy test for women with child-bearing
             potential

          -  Ejection fraction of &gt;= 45%

        Exclusion Criteria:

          -  Subjects with FAM B3

          -  Must not be receiving chemotherapy (except Hydroxyurea)

          -  Not receiving growth factors, except for erythropoietin

          -  Subjects with a &quot;currently active&quot; second malignancy other than non-melanoma skin
             cancers

          -  Subjects with uncontrolled high blood pressure, unstable angina, symptomatic
             congestive heart failure, MI within the last 6 months or uncontrolled cardiac
             arrhythmia

          -  Subjects taking diltiazem

          -  Subjects who require HIV protease inhibitors or those with AIDS-related illnesses

          -  No evidence of cerebellar dysfunction at baseline or during prior cytarabine therapy

          -  Not pregnant or breastfeeding

          -  Uncontrolled infection

          -  Subjects taking Carbamazepine, Rifabutin, Rifampin, Rifapentine, St. John's wort,
             Clarithromycin, Cyclosporine, Diltiazem, Erythromycin, Telithromycin, Verapamil,
             Tacrolimus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pennsylvania Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2008</study_first_submitted>
  <study_first_submitted_qc>October 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2008</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <name_title>Selina Luger, M.D.</name_title>
    <organization>University of Pennsylvania Abramson Cancer Center</organization>
  </responsible_party>
  <keyword>Advanced myeloid leukemias</keyword>
  <keyword>AML</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Relapsed myeloid leukemias</keyword>
  <keyword>Refractory myeloid leukemias</keyword>
  <keyword>MEC</keyword>
  <keyword>Rapamycin</keyword>
  <keyword>Sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

